Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients

Bookmark and Share
Published: 18 Dec 2019
Views: 701
Dr Luca Gianni - San Raffaele Hospital, Milan, Italy

Dr Luca Gianni gives a press conference at the 2019 San Antonio Breast Cancer Symposium about the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer (TNBC).

Watch our interview with Dr Luca Gianni here.

Read more about the study here